TABLE OF CONTENTS
Volume 11, Issue 3 (April 2005)
Editorial
Editorial: Is the UK NHS a good place to do clinical trials?
Jan Steiner
J Commer Biotechnol 11: 205-207; doi:10.1057/palgrave.jcb.3040118
Miscellaneous
Introduction to the debate: How much regulation do we want or need?
Derek Burke
J Commer Biotechnol 11: 208; doi:10.1057/palgrave.jcb.3040119
Papers
NGO war on biotechnology
Henry I Miller and Gregory Conko
J Commer Biotechnol 11: 209-222; doi:10.1057/palgrave.jcb.3040120
Plant biotechnology, the regulator and the consumer
Janet Bainbridge OBE
J Commer Biotechnol 11: 222-227; doi:10.1057/palgrave.jcb.3040121
The latest orphan drug designations and the Commission Communication on Regulation (EC) 141/2000
Rashmi R Shah
J Commer Biotechnol 11: 228-238; doi:10.1057/palgrave.jcb.3040122
Corporate development in biotechnology in 2005
Alan Williams
J Commer Biotechnol 11: 239-248; doi:10.1057/palgrave.jcb.3040123
Distribution of data and unique material resources made with NIH funding
Mark L Rohrbaugh
J Commer Biotechnol 11: 249-262; doi:10.1057/palgrave.jcb.3040124
Amgen v TKT: Assessment of inventive concept is crucial for assessing infringement of biotechnology patents
William Cook
J Commer Biotechnol 11: 263-270; doi:10.1057/palgrave.jcb.3040125
The quest for generic biotechnology pharmaceuticals in the USA
Thomas J Kowalski, Pamela Fekete and Anne-Marie C Yvon
J Commer Biotechnol 11: 271-274; doi:10.1057/palgrave.jcb.3040126
The DNA/RNA market to 2010
Mark Belsey and Alex K Pavlou BSc, MSc, PhD
J Commer Biotechnol 11: 275-278; doi:10.1057/palgrave.jcb.3040127
Miscellaneous
Legal and regulatory update
John Wilkinson and Frederick J Dorey
J Commer Biotechnol 11: 279-288; doi:10.1057/palgrave.jcb.3040128
